Overview
Nidal meningioma (also called a hemangiopericytoma‑like meningioma or “angiomatous meningioma”) is a rare subtype of meningioma that displays a honey‑comb or “nidus” pattern of tightly packed blood‑filled spaces on microscopic examination. Like all meningiomas, it originates from the meninges—the protective membranes that surround the brain and spinal cord.
- Typical age: Most patients are diagnosed between 40 and 70 years old, with a median age of ~55 years.
- Sex distribution: Women are affected about 2–3 times more often than men, mirroring the overall meningioma pattern.
- Prevalence: Nidal meningiomas represent roughly <1–2 % of all meningiomas, which themselves account for about 30 % of primary brain tumors in adults (≈ 200,000 new cases annually worldwide) [1][2].
Because they are uncommon, data on exact incidence are limited, but large pathology registries suggest an incidence of 0.5–1 case per million people per year.
Symptoms
The clinical picture depends on the tumor’s size, location, and rate of growth. Nidal meningiomas most often arise along the convexities of the cerebral hemispheres, the falx cerebri, or the spinal meninges.
- Headache – dull, persistent, often worse in the morning or when lying down.
- Seizures – focal seizures are the most common presenting symptom for cortical lesions.
- Motor weakness – difficulty lifting an arm or leg on the side opposite the tumor.
- Sensory changes – numbness, tingling, or a “pins‑and‑needles” sensation.
- Visual disturbances – double vision, loss of peripheral vision, or eye movement problems if the tumor compresses the optic pathways.
- Hearing loss or tinnitus – when located near the cerebellopontine angle.
- Cognitive or personality changes – memory lapses, difficulty concentrating, or mood swings.
- Balance and coordination problems – particularly with posterior fossa (near the cerebellum) lesions.
- Spinal symptoms – back pain, radicular pain, or weakness in the limbs if the tumor is intradural‑extramedullary.
- Hydrocephalus symptoms – nausea, vomiting, gait instability, and worsening headache due to blocked cerebrospinal fluid flow.
Because many of these symptoms overlap with other neurological conditions, imaging is essential for an accurate diagnosis.
Causes and Risk Factors
Most meningiomas, including the nidal variant, are sporadic. However, several factors increase the likelihood of developing one.
Genetic and Molecular Factors
- NF2 gene mutation – Loss‑of‑function mutations on chromosome 22q are found in up to 60 % of sporadic meningiomas and almost all patients with Neurofibromatosis type 2, a hereditary syndrome that predisposes to multiple meningiomas [3].
- Other chromosomal alterations – Deletions of 1p, 14q, and mutations in TRAF7, KLF4, or AKT1 can be present, though their role in the nidal subtype is less clear.
Hormonal Influence
- Estrogen and progesterone receptors are expressed in up to 80 % of meningiomas, which may explain the female predominance. Hormonal fluctuations during pregnancy can accelerate growth.
Environmental and Lifestyle Factors
- Ionizing radiation – Prior therapeutic head or neck radiation (e.g., for childhood cancer) raises risk by 3‑ to 5‑fold [4].
- Cell phone use – Current evidence is inconclusive, but long‑term, high‑frequency exposure is still under investigation.
- Obesity – Higher body mass index correlates with increased meningioma incidence, possibly via altered hormone metabolism.
Other Risk Modifiers
- Age (risk rises sharply after 40 years).
- Family history of meningioma or NF2.
Diagnosis
Diagnosing a nidal meningioma involves a combination of clinical assessment, imaging studies, and, when necessary, histopathologic confirmation.
Neuro‑imaging
- Magnetic Resonance Imaging (MRI) with contrast – The gold standard. Typical findings:
- Well‑circumscribed, extra‑axial mass attached to dura.
- Iso‑ to slightly hypointense on T1‑weighted images, hyperintense on T2.
- Strong, homogeneous gadolinium enhancement.
- “Dural tail” sign in many cases.
- In nidal subtype, internal flow‑voids or a “cloud‑like” vascular pattern may be seen.
- Computed Tomography (CT) scan – Helpful for detecting calcifications and bone remodeling.
- Angiography (DSA or MR‑angiography) – Occasionally performed when pre‑operative embolization is considered.
Histopathology
Definitive diagnosis requires tissue obtained via surgical resection or stereotactic biopsy. Under the microscope, nidal meningioma shows:
- Clusters of small, capillary‑like blood vessels forming a “nidus.”
- Blunt‑ended (epithelioid) cells with low mitotic activity (WHO Grade I).
- Immunohistochemistry: EMA+, vimentin+, and often progesterone receptor positive; Ki‑67 (MIB‑1) labeling index <3 %.
Additional Work‑up
- Neurological examination – Baseline assessment of motor, sensory, cranial nerve function.
- Neuro‑cognitive testing – For patients with subtle memory or personality changes.
- Baseline labs – CBC, coagulation profile, and renal function if surgery or embolization is planned.
Treatment Options
Management is individualized based on tumor size, location, symptom burden, patient age, and overall health.
1. Observation (Watchful Waiting)
- Indicated for small (<3 cm), asymptomatic lesions with low growth rate.
- Serial MRI every 6–12 months for the first 2 years, then annually.
- Appropriate for elderly patients or those with significant surgical risk.
2. Surgical Resection
Complete (Simpson Grade I) resection offers the highest cure rate for WHO Grade I meningiomas.
- Approach selection – Craniotomy tailored to tumor location (e.g., frontal, retrosigmoid, posterior fossa).
- Goal – Remove tumor and involved dura; if dura is infiltrated, a wide dural margin is taken.
- Outcomes – 5‑year progression‑free survival >90 % for gross total resection of Grade I tumors [5].
- Risks – Bleeding (particularly in the vascular nidal subtype), cranial nerve deficits, infection, CSF leak.
3. Radiotherapy
- External Beam Radiation Therapy (EBRT) – Used when resection is subtotal or not feasible.
- Stereotactic Radiosurgery (SRS) (Gamma Knife, CyberKnife) – Delivers a high dose in 1–3 sessions; ideal for ≤3 cm lesions.
- Control rates for WHO Grade I meningioma after SRS: 90‑95 % at 5 years [6].
4. Endovascular Embolization
Pre‑operative embolization reduces intra‑operative blood loss, especially useful for highly vascular nidal meningiomas. Performed by interventional neuroradiologists using particles or liquid agents.
5. Medical Therapy
- Hormonal therapy – Limited evidence; some clinicians trial medroxyprogesterone acetate in recurrent disease.
- Targeted agents – For atypical or aggressive meningiomas, drugs like everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are being studied, but not standard for nidal subtype.
6. Lifestyle & Supportive Measures
- Vaccination against meningitis if the tumor compromises CSF pathways.
- Pain management with acetaminophen or NSAIDs (avoid high‑dose opioids when possible).
- Physical therapy for postoperative motor deficits.
- Neuro‑psychological counseling for mood or cognitive changes.
Living with Nidal Meningioma
Even after successful treatment, long‑term follow‑up and lifestyle adjustments help maintain quality of life.
Follow‑up Schedule
- First MRI at 3 months post‑surgery or radiosurgery, then at 12 months, and annually thereafter for at least 5 years.
- Neurological exams at each oncology or neurosurgery visit.
Daily Management Tips
- Headache diary – Track frequency, severity, and triggers.
- Seizure precautions – If seizures occur, wear a medical alert bracelet, avoid driving until cleared, and keep rescue medication (e.g., rectal diazepam) handy.
- Activity modifications – Gradual return to exercise; avoid heavy lifting (>10 kg) for 6 weeks post‑op.
- Sleep hygiene – Adequate rest reduces headache and seizure risk.
- Stress reduction – Mindfulness, yoga, or counseling can improve cognitive symptoms.
- Nutrition – Balanced diet rich in omega‑3 fatty acids, antioxidants, and adequate hydration.
- Medication adherence – Take antiepileptic drugs exactly as prescribed; never stop abruptly.
Support Resources
- American Brain Tumor Association (ABTA) – patient education and support groups.
- National Organization for Rare Disorders (NORD) – information on rare meningioma subtypes.
- Local neuro‑oncology or neurosurgery clinics – many offer multidisciplinary survivorship programs.
Prevention
Because most nidal meningiomas are sporadic, true primary prevention is limited. However, risk reduction strategies are recommended.
- Avoid unnecessary head/neck radiation – Discuss alternative imaging or treatment options with your physician.
- Control hormonal risk – For women on long‑term hormone replacement therapy (HRT), discuss the lowest effective dose and periodic re‑evaluation.
- Maintain healthy weight – Obesity is a modifiable risk factor; aim for BMI < 25 kg/m².
- Use protective equipment – Wear helmets when engaging in high‑impact sports or biking.
- Regular medical check‑ups – Early imaging for patients with NF2 or a strong family history can catch tumors before they cause symptoms.
Complications
If a nidal meningioma is left untreated or incompletely treated, several complications may arise.
- Neurological deficits – Permanent weakness, sensory loss, or visual impairment depending on tumor location.
- Seizure disorder – Chronic epilepsy often requires lifelong antiepileptic therapy.
- Hydrocephalus – Obstructed CSF flow can lead to increased intracranial pressure, requiring shunt placement.
- Mass effect and herniation – Large tumors can cause brain shift, a life‑threatening emergency.
- Recurrence – Approximately 10‑15 % of WHO Grade I meningiomas recur after gross total resection; risk is higher after subtotal removal.
- Post‑operative complications – Infection, wound dehiscence, CSF leak, or venous sinus thrombosis.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Sudden, severe headache described as “the worst headache of my life.”
- New onset of seizures, especially if they last longer than 5 minutes or occur in a cluster.
- Rapidly worsening weakness or loss of movement on one side of the body.
- Sudden vision loss, double vision, or eye movement abnormalities.
- Profound confusion, difficulty speaking, or loss of consciousness.
- Vomiting that is not related to a stomach bug and is accompanied by headache or altered mental status.
- Signs of increased intracranial pressure: bulging eyes, papilledema (visible swelling of the optic disc), or a “thick” neck.
These symptoms may indicate tumor growth, hemorrhage, or acute brain swelling, all of which require prompt medical evaluation.
References
- Mayo Clinic. Meningioma: Symptoms & Causes. https://www.mayoclinic.org/diseases-conditions/meningioma/symptoms-causes/syc-20375587 (accessed May 2026).
- World Health Organization. WHO Classification of Tumors of the Central Nervous System, 2021. International Agency for Research on Cancer, 2021.
- National Institutes of Health. Neurofibromatosis Type 2. https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-2 (accessed May 2026).
- Center for Disease Control and Prevention. Radiation Exposure and Brain Tumors. https://www.cdc.gov/cancer/radiation (accessed May 2026).
- Cleveland Clinic. Meningioma Treatment Options. https://my.clevelandclinic.org/health/diseases/15886-meningioma (accessed May 2026).
- European Journal of Neurology. Kondziolka D, et al. Stereotactic radiosurgery for meningiomas: long‑term outcomes. Eur J Neurol. 2020;27:173‑180.